Landscape Capital Management L.L.C. Acquires New Holdings in Royalty Pharma PLC $RPRX

Landscape Capital Management L.L.C. purchased a new stake in Royalty Pharma PLC (NASDAQ:RPRX – Free Report) during the third quarter, according to its most recent filing with the SEC. The firm purchased 15,313 shares of the biopharmaceutical company’s stock, valued at approximately $894,000.

Several other large investors have also recently made changes to their positions in RPRX. Bank of America Corp DE lifted its position in shares of Royalty Pharma by 29.0% during the first quarter. Bank of America Corp DE now owns 3,495,846 shares of the biopharmaceutical company’s stock valued at $167,696,000 after buying an additional 786,921 shares during the last quarter. Amundi increased its holdings in Royalty Pharma by 15.3% in the 1st quarter. Amundi now owns 3,088,773 shares of the biopharmaceutical company’s stock worth $148,168,000 after buying an additional 409,394 shares during the period. Dorsey Asset Management LLC lifted its position in Royalty Pharma by 0.8% during the first quarter. Dorsey Asset Management LLC now owns 2,276,570 shares of the biopharmaceutical company’s stock valued at $109,207,000 after purchasing an additional 17,101 shares during the period. Robeco Institutional Asset Management B.V. raised its position in Royalty Pharma by 28.2% during the third quarter. Robeco Institutional Asset Management B.V. now owns 1,168,427 shares of the biopharmaceutical company’s stock valued at $68,189,000 after acquiring an additional 256,841 shares in the last quarter. Finally, Danske Bank A S lifted its stake in shares of Royalty Pharma by 44.4% in the 3rd quarter. Danske Bank A S now owns 1,107,117 shares of the biopharmaceutical company’s stock valued at $64,611,000 after purchasing an additional 340,439 shares during the period. 54.35% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. The Goldman Sachs Group reiterated a “buy” rating and set a $66.00 price target on shares of Royalty Pharma in a research report on Thursday, August 6th. Morgan Stanley upped their price objective on shares of Royalty Pharma from $65.00 to $67.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Citigroup boosted their target price on shares of Royalty Pharma from $70.00 to $78.00 and gave the stock a “buy” rating in a research note on Thursday, November 5th. TD Cowen lifted their price objective on Royalty Pharma from $68.00 to $80.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Zacks Research raised shares of Royalty Pharma from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company. According to MarketBeat, Royalty Pharma presently has an average rating of “Buy” and an average target price of $65.00.

View Our Latest Analysis on Royalty Pharma

Insider Buying and Selling

In other Royalty Pharma news, EVP Marshall Urist sold 4,126 shares of the stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $57.10, for a total value of $235,594.60. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 100,000 shares of the company’s stock in a transaction on Tuesday, November 17th. The shares were sold at an average price of $68.15, for a total transaction of $6,815,000.00. Following the completion of the transaction, the executive vice president owned 177,523 shares of the company’s stock, valued at $12,098,192.45. This represents a 36.03% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 440,788 shares of company stock worth $29,157,162. Corporate insiders own 18.84% of the company’s stock.

Royalty Pharma Price Performance

Shares of RPRX opened at $67.72 on Friday. Royalty Pharma PLC has a fifty-two week low of $37.31 and a fifty-two week high of $70.37. The company has a market cap of $38.84 billion, a P/E ratio of 56.43, a PEG ratio of 1.36 and a beta of 0.37. The company has a quick ratio of 1.29, a current ratio of 1.29 and a debt-to-equity ratio of 0.77. The firm’s 50 day moving average price is $62.11 and its 200 day moving average price is $55.08.

Royalty Pharma Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be paid a dividend of $0.2350 per share. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date is Friday, November 13th. Royalty Pharma’s dividend payout ratio is presently 78.33%.

Royalty Pharma Company Profile

(Free Report)

Royalty Pharma plc is a biopharmaceutical royalty company that provides funding to companies and inventors in exchange for royalty interests in medicines. It acquires existing royalties and helps finance drug development and commercialization through royalty-based transactions and other forms of funding. The company’s portfolio includes royalty interests in medicines across a range of therapeutic areas, spanning both approved treatments and products in development. Royalty Pharma generally earns revenue when these medicines are sold; it does not operate as a conventional drug manufacturer or commercialize medicines itself.

Further Reading

Institutional Ownership by Quarter for Royalty Pharma (NASDAQ:RPRX)

Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.